Barrington Research Issues Positive Forecast for LeMaitre Vascular (NASDAQ:LMAT) Stock Price

LeMaitre Vascular (NASDAQ:LMAT) had its price target hoisted by equities researchers at Barrington Research from $92.00 to $93.00 in a research report issued on Friday, Benzinga reports. The firm presently has an “outperform” rating on the medical instruments supplier’s stock. Barrington Research’s price target would indicate a potential downside of 7.00% from the stock’s current price.

A number of other research analysts have also recently weighed in on the stock. JMP Securities raised their price objective on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 20th. Cantor Fitzgerald started coverage on shares of LeMaitre Vascular in a research note on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price target on the stock. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Tuesday, August 27th. Finally, Lake Street Capital began coverage on LeMaitre Vascular in a research note on Friday, August 2nd. They set a “buy” rating and a $105.00 price target on the stock. Three analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $94.83.

LeMaitre Vascular Trading Up 13.1 %

LMAT stock traded up $11.61 during trading on Friday, hitting $100.00. 75,711 shares of the company’s stock were exchanged, compared to its average volume of 122,084. The business has a 50-day moving average price of $89.53 and a two-hundred day moving average price of $82.77. The stock has a market capitalization of $2.25 billion, a price-to-earnings ratio of 59.89, a PEG ratio of 2.33 and a beta of 0.88. LeMaitre Vascular has a 52-week low of $45.96 and a 52-week high of $101.67.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The business had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a return on equity of 12.41% and a net margin of 18.33%. The company’s revenue for the quarter was up 15.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.33 earnings per share. On average, equities research analysts anticipate that LeMaitre Vascular will post 1.86 earnings per share for the current fiscal year.

Insider Buying and Selling at LeMaitre Vascular

In related news, Director David B. Roberts sold 3,063 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total transaction of $251,380.41. Following the sale, the director now directly owns 14,114 shares in the company, valued at approximately $1,158,335.98. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 10.79% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On LeMaitre Vascular

Institutional investors and hedge funds have recently made changes to their positions in the business. Summit Global Investments raised its position in shares of LeMaitre Vascular by 2.4% during the 3rd quarter. Summit Global Investments now owns 6,192 shares of the medical instruments supplier’s stock worth $575,000 after purchasing an additional 146 shares during the period. Shaker Investments LLC OH lifted its stake in LeMaitre Vascular by 1.3% during the second quarter. Shaker Investments LLC OH now owns 13,833 shares of the medical instruments supplier’s stock valued at $1,138,000 after buying an additional 175 shares in the last quarter. NBC Securities Inc. boosted its position in shares of LeMaitre Vascular by 73.2% in the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 183 shares during the period. GAMMA Investing LLC raised its position in LeMaitre Vascular by 34.3% during the third quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock valued at $68,000 after buying an additional 188 shares during the period. Finally, nVerses Capital LLC lifted its stake in LeMaitre Vascular by 33.3% in the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock worth $66,000 after acquiring an additional 200 shares in the last quarter. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.